Hello and welcome to the Unum Group 3Q 2021 Earnings Conference Call. My name is Robin and I will be coordinating your call today. [Operator Instructions] I will now hand you over to your host, Tom White, from Unum Group. Tom, please go ahead.

Great. Thank you, Robin. Good morning, everyone and welcome to the Third Quarter 2021 Earnings Conference Call for Unum. Our remarks today will include forward-looking statements, which are statements that are not of current or historical fact. As a result, actual results might differ materially from results suggested by these forward-looking statements. Information concerning factors that could cause results to differ appears in our filings with the Securities and Exchange Commission and are also located in the sections titled Cautionary Statement Regarding Forward-Looking Statements and Risk Factors in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020, and our subsequently filed Form 10-Qs. Our SEC filings can be found in the Investors section of our website at unum.com. I remind you that the statements in today's call speak only as of the date they are made and we undertake no obligation to publicly update or revise any forward-looking statements. A presentation of the most directly comparable GAAP measures and reconciliations of any non-GAAP financial measures included in today's presentation can be found in our statistical supplement on our website in the Investors section. So yesterday afternoon, Unum reported third quarter 2021 Net Income of $328.6 million or $1.60 per diluted common share compared to $231.1 million or $1.13 per diluted common share in the third quarter of 2020. Net income for the third quarter of 2021 included the after-tax impairment loss on internal use software of $9.6 million or $0.05 per diluted common share. The after-tax amortization of the cost of reinsurance of $15.5 million or $0.08 per diluted common share. The net after-tax reserve decrease related to reserve assumption updates of $143.3 million or $0.70 per diluted common share, and a net after-tax realized investment loss on the Company's investment portfolio of $100,000 or a de minimis impact on earnings per diluted common share. Net income in the third quarter of 2020 included after-tax costs related to an organizational design update of $18.6 million or $0.09 per diluted common share, and a net after-tax realized investment gain on the Company's investment portfolio of $3.8 million or $0.01 per diluted common share. Excluding these items after-tax adjusted operating income in the third quarter of 2021 was $210.5 million or $1.03 per diluted common share. Compared to $245.9 million or $1.21 per diluted common share in the year-ago quarter. Participating in this morning's conference call are Unum's President and CEO, Richard McKenney, Chief Financial Officer, Steven Zabel, and Chief Operating Officer Michael Simonds, as well as Mark Till who heads our Unum international business and Tim Arnold who heads our Colonial Life and voluntary benefits businesses. And now I will turn the call over to Ric for his opening comments.

Thank you, Tom. Good morning everyone, and thank you for joining us today. As we look at our third quarter earnings results this morning, let me start by highlighting that our core business has continued to perform well. We saw top-line growth in our business lines at good returns. We also recognized a continued challenge that COVID presents on our near-term results. It has cast a shadow on our core returns but we still see a great business that we believe will return to the levels of profitability that we expect. Let me start with the overall operations before commenting on these COVID trends. I would first highlight that core premium growth has been steady and tracking to the expectations we previously laid out for you. On a year-over-year basis in the third quarter Unum U.S. generated an increase in premium income of 1.2%. Colonial Life was slightly better than breakeven falling 3 previous quarters with negative comparisons and our International lines also generated positive premium trends. This premium growth momentum is building back as sales growth re-emerges, persistency remains favorable and the external environment of employment growth and wage inflation benefits our business. Outside of the COVID related impacts, we remain very encouraged with the benefits experience and operating income contributions from our other business lines. The Supplemental and Voluntary lines, Colonial Life, our International Businesses and our Closed Block segment all show generally stable results and made substantial contributions to income this quarter. We're also pleased with our overall investment results this quarter. It was another quarter for strong returns from our alternative investments and also another quarter of higher-than-normal bond call premiums. The underlying credit quality of the portfolio is excellent and the investment team remains diligent in their analysis of our credits through the changing market…

Great. Thank you, Ric, and good morning, everyone. As I discussed our third quarter financial results this morning, I will again primarily focus on analysis of our third-quarter results relative to the second quarter of 2021, which allows us to show how the Company's business lines are progressing through the pandemic. I will also describe our adjusted operating income results by segment excluding the impacts from our GAAP reserve assumption updates. As we outlined in the press release, the net reserve decrease related to our annual reserve assumption update totaled $181.4 million before tax or $143.3 million after-tax. The biggest component of the actuarial reserve review was the release of $215 million before tax in the Unum U.S. Long-Term Disability line. Claim reserves should represent our best estimate of the future liability and since the last GAAP reserve review, investments in our operations have impacted our claims management and resulted in improvements in claim recoveries over the past several years, which we now believe are sustainable. At such, these reserves have been adjusted to better reflect the expected costs of claims. This reserve update will have little impact on our forward expectations for earnings from this line or the expected benefit ratio. The reserve review also determine that reserve should be increased in three lines within the Closed Block reporting segment. For the closed group pension block, policy reserves were increased by $25.1 million before tax. For the closed disability block, claim reserves were increased by $6.4 million before tax. And finally, for long-term care, claim reserves were increased by $2.1 million before tax. Although the net of these reserve updates are excluded from adjusted operating income, they did contribute on $0.70 per share to the Company's book value. I'll start the discussion of our operating results with the Unum…

Thank you, Steven. Just a couple of closing thoughts. We do continue to be pleased with the operational performance of the Company through what has been an extraordinary environment. We believe we are really well positioned to benefit from today's strong business conditions and we have to remain vigilant as COVID-related mortality and infection rates continue to persist. The team's here to respond to your questions, so I'll ask Robin to begin the Q&A session, Robin.

Thank you. If you would like to ask a question, [Operator instructions] We would kind of limit your question to one and one follow-up question. When preparing to ask your question please make sure that your phone is unmuted likely. Our first question is from Ryan Krueger from K BW. Ryan, please go ahead.

Hey, thanks. Good morning. First, could you just remind us what is the remaining amount of the main PDR that you have left to fund?

Steve?

Yeah, here, Ryan, it's Steve. I'll go back to kind of what we've disclosed in the past. Originally, the permitted practice that we had related to the PDR was that we would need to increase our LTC reserves by $2.1 billion over the 7-year period. We did have an increment last year of $229 million or just south of $230 million, We'll continue to assess that as we go through the remainder of the 7-year period. And so we'll have our year-end work for statutory reserves coming up this quarter and we can talk more about what the 2021 increment there would look like.

Thanks. And then on LDTI, I know you're not ready to share the quantitative impacts yet, but can you give us any sense of how far along you are in discussions with the rating agencies and how they're thinking about the GAAP book value decline in potential implications to acceptable leverage ratios?

Yeah. We're in constant communication with the rating agencies. And to-date, I would say those conversations are somewhat similar to what we've discussed, where they understand this is an account -- GAAP accounting pronouncement, doesn't affect cash flow, is not going to affect coverage and our ability to service our debt. And so those conversations will be get -- ongoing. I'm sure they're having conversations with many others around that as well. So those will continue in the next year as we get closer to adoption.

Great. Thank you.

Thanks, Ryan.

[Indiscernible]

Thank you. Our next question is from Jimmy Bhullar from JPMorgan. Jimmy, please go ahead.

Hi. Good morning. So on buybacks, I just had a question about, do you intend to complete the program by the end of next year or is that amount that you've outlined in just a policyholders and what you do will depend on the environment?

Hi, Jimmy, it's Ric. Yes, we do intended to do that, so we put out the 250 million authorization that is our plans for next year. We'll get into the details as we get to laying out a full 2022 outlook. But that is not a policyholders that's kind of factored into our plans we've done then. It's part of why you're seeing us do 50 million here in the fourth quarter and that's the general run rate that you might see, although it might deviate over the course of the year based on what we're seeing but that is our expectation.

And then any thoughts on like why you wouldn't -- especially if the stock is a lot weaker in the near-term, why would you not do even more than that if you've already sort of earmarked that gap to why wouldn't you just do more than 50 in the near-term to take advantage of the stock base.

Jimmy, when we look out over the course of the next year, the 250 that I just mentioned, we -- like I said, it may deviate by quarter based on market conditions, so I don't want to think that's an even level, but we're going to pace this in. We just started this authorization -- just got approval for that last week, so we'll pace our way into it and I'm sure we'll have more to say as we get through the first quarter -- I'm sorry, the fourth-quarter reporting period.

Okay. And then when do you expect to give out details on the impact on your business from the changes in accounting for the long duration products?

Yeah, I can take that one. We haven't really set a firm date on it but we imagine it will be consistent with many others, in the first half of next year we'll start to talk more quantitatively about that.

Okay. And then just lastly, can you compare and contrast what's going on in the U.S. with COVID and international doesn't seem like there's much of an impact obviously, fewer deaths in the markets but Europe versus the U.S. But why is it having a surprisingly greater impact in the U.S. and not as much of an impact in UK or Poland?

Jimmy, that's a really good question and I think it's one we can explore a little bit because I think given our exposures in each of the countries and they're going through COVID very differently at the moment. So Mike, maybe you can give an overview and we can talk to Mark as well, International.

Sure. Thanks. Good morning, Jimmy. I think you've put on an important point of distinction and we are seeing as Steve covered in his comments, pretty acute impact in our short-term disability line which has got that Group Disability loss ratio elevated and obviously in Group Life and in our voluntary both the Colonial brands and the Unum brands here in the U.S. no doubt, I think the practices around COVID in the UK as well as some elements of business mix, represent points of distinction and maybe Mark, you want to speak to that?

Yeah, Jimmy, I think the biggest difference in the U.K. is the vaccination rate and there was something that came out from the U.K. Office of Statistics about 2 days ago that said the death rate -- the mortality rate amongst the vaccinated -- unvaccinated population was 850 per 100,000 but amongst the vaccinated population was only 26 per 100,000. And in the UK, we've got 90% in vaccination rates amongst adults. So it's that vaccine piece that's making the biggest difference to mortality and in -- and also hospitalization and therefore impacts on Disability claims.

Okay. And then just lastly, it's a little surprising that everybody sort of knows that the pandemic is going on, but nobody seems to have adjusted prices in the Group Life business going into renewal season so I realize it's sort of an unusual time, but those are mostly one-year policies. So any thoughts on like it -- I guess if somebody were to raise prices, they most likely move the case anyway if they were raising amount by a lot but any thoughts on why pricing for Group Life has not adjusted at least even a little bit for what's going on and that shifting more towards the younger age cohort?

Thanks Jimmy. [Indiscernible] maybe I will take that one. I can speak to our pricing strategy a little less so to other carriers in the market, I'd say for us, our objective always is to manage price on a gradual basis so that our clients can anticipate what is coming do. So relatively conservatively so that they're not getting last minute changes to what they're going to see on their expense line. And so we've been feathering in COVID-related pricing this year into the new business and the renewal up-markets. And we've done that on the Life Insurance side, I expect that feathering in will increase as we go through the fourth quarter and into next year. A little bit more gradually on the disability side, as well. Particularly around short-term disability. And so a couple of thoughts around the impact. Do you think that becomes a way that we moderate back to our long-term expectation in the Group Life loss ratio, as well as in Group Disability? Second, I do anticipate that we will see some pressure in new business sales, particularly in the mid and large case Group Life and Group Disability segment. I share some of your curiosity around why the industry hasn't moved as quickly. I do anticipate that that will happen over time. Just may take a few quarters to get there. I'd kind of wrap it up though by saying most critically to us is our clients sticking with us through those gradual rate increases. And as I look forward to the January 1st, which is an important effective date for the Group insurance lines, we're seeing persistency, the tracking actually, just a tick or 2 above expectation, and that's while placing a reasonably substantial amount of rate increase. So we've been there in 2020 and 2021 for our clients. We've been delivering through a really challenging period of time. And that it's gratifying to see them stick with us.

Okay. Thank you.

Thanks, Jimmy. I'll ask you. We do have, people, 1 question, 1 follow-up. I think Jimmy got a couple in there, so we got a few people to get through. So please, just 1 and 1 follow up. Go ahead. Who's next?

Thank you. The next question is Tom Gallagher from Evercore ISI. And just a reminder, it will be one question and one follow-up. Thank you. Tom, please go ahead.

I got those instructions, thank you. My 10-part question will be shelved for this morning. My main question is on Disability Benefit ratio, the 79 that you had this quarter, should we -- is that a good placeholder into Q4 or is there anything that you thought was not trendable in that result?

Hey, Tom, it's Mike. Yes, I mean I've certainly given up trying to predict exactly what's going to happen in any given quarter. But as we look at the elevation of COVID-related short-term disability being the primary driver of that elevated group dis overall, it feels like that's a reasonable placeholder as we go into fourth quarter. We've mentioned it a little bit, but you see a little bit of elevated incidents on the LTD, that's a watch item for us. Fortunately, the recoveries from the benefits team that we've got here in-house have been above expectation and have offset that new claim incidence. But it is higher than our longer-term expectation. And until the external environment I think settles a bit, that's a reasonable placeholder.

Okay, thanks. And then my follow-up is just trying to do some of these calculations for LDTI. I realize you're not going to quantify the overall expected impact at this point, but can you answer one question for me? Your active life reserve liability duration on your long term care block, would that be closer to 15 years, 20 years, 25 years? Can you give me some help on that one?

Yeah, Tom, we don't really disclose that level of detail on duration for LTC what -- when -- and I know where you're going and so I'd reiterate something that I said in the script. And that's just that -- our view would be that the vast majority of the impact that we're going to have in adoption is really the differential just between our investment strategy, whether it's around liquidity to your point, the duration of our liabilities and how we think about what types of assets match up well with that, the credit profile of our portfolio and just how that differs from just a straight generally consistent Single A type of portfolio that's going to drive the majority of the differential upon adoption.

Got you. Okay. Thanks.

Thanks, Tom.

Thank you, Tom.

Thank you, Tom. Our next question is from Erik Bass from Autonomous Research. Go ahead, Erik.

Hi, thank you. And Mike, maybe want to come back to the Long-Term Disability claims incidents that you mentioned and saw this quarter. Do you have any sense of what's driving this and is there any signs long COVID impacts beginning to emerge and causing STD claims to move into LTD claims?

Thanks for the question. I mean, there's a little bit of that certainly with this long COVID that's not really the driver of the LTD incident. I'd say it's just more generally claims coming in that we've seen in other instances where there is pretty aggressive change in the external environment. And these are claim types actually that we were actually pretty good at managing. We've got really, really good vocational and clinical resources that we apply to those. I think we're increasingly weaving really good data and analytics to help really sharpen the focus of those precious resources on the individuals where we're going to see the best impact from a recovery point-of-view. So we've certainly got unsettled period of time that we've got a weather here but I feel really, really confident about the team and our ability to get back to where that long-term ranges as the environment settles a bit.

Got it. Thank you. And then for Group Life COVID claims was the sensitivity to population deaths pretty consistent across the quarter? Or have you seen any of the percentage of claims or the average claim size continued to trend higher?

Yes. This Steve. I would say the trend we've seen is that early in the pandemic, our average claim size was right around $50,000 per client. There were some months that is even a little bit less than that. Now it's pretty consistent. And then I'd say what you saw pretty consistent when vaccination started to roll-out, our average age starting to come down pretty dramatically. And as it did, I would say last quarter, second quarter, our average claim size was about 55,000. And then this quarter, it was a little over 60,000 and that's just really consistent with what we saw in just the age demographics of those people that were in our claim population.

Got it. So basically we should watch the percentage of population being in the working age cohorts as a driver of severity?

Yes. And I would say going into the fourth quarter, the level of vaccinations probably remain fairly consistent with what we've seen. I mean, it may tick up a little bit, but I would say the kind of 60,000 range is probably pretty good, maybe a tick higher. I don't see it dramatically increasing from where it is today, but we'll just have to see how it plays out.

Got it. Thank you.

Yes.

Thank you, Erik. On next question is from Tracy Benguigui from Barclays? Tracy, please go ahead.

Thank you. Good morning. Just a follow-up on Ryan's question on PDR. You mentioned that your acceleration can you completion as early as the end of 2024 or will that be like a straight line amortization or will that be lumpy because it's incremental to get there? I guess around getting at like would you have an annual run-rate of accelerated Pre-funding that you're thinking about?

Yeah. I would say the acceleration of the recognition will follow pretty closely with a level of share buybacks that we execute in any one period that -- that'll be a fairly consistent number. that the PDR itself will just -- it's calculated after the end of every period and that isn't necessarily straight line. It kind of lags in overtime, but I would say that the kind of additional incremental capital that we're going to put behind that in the recognition of the PDR, the incremental recognition that PDR will be pretty consistent with the buyback levels.

That's very helpful. And just another question on, LDTI on future disclosure. You've talked in the past about cash flows. But will we see more details on that or any new non-GAAP metric that better align with the way you view your business economically speaking.

Yeah, it's a good question and it's something that we're going to have to work out. And clearly, the disclosures that we are going to have to make are pretty prescriptive. I would also say that, I think the SEC is probably going to be pretty clear that this accounting pronouncement needs to be applied and reflected in the earnings that you report. I'm not sure there's going to be a lot of leeway for non-GAAP adjustments. So I think for us, we're going to need to really come back and really make sure people understand what is the cash flow generation of the business. Because at the end of the day that really drives the health of our business and is a better indicator of really the capital that we have to deploy to grow the business and to return capital to our shareholders. I think we'll just continue to stress what our capital generation and deployment model are, but we'll have to follow the accounting guidance as it played out.

Yeah. No, I totally got that. I guess if I were to make a parallel on IFRS 17, I think there's now introduction of new supplement. So when it change the accounting rules, it would just has add an additional land for that to have speaking about.

Yeah. And I -- Tracy, I think that this is going to evolve how the industry tries to explain the economic performance of the business. So we'll stay close to that, stay close to what our peers maybe are reporting and how they're addressing it as we go towards adoption.

Okay. Great. Thank you.

Thank you, Tracy.

Thanks, Tracy.

Thank you, Tracy. Our next question is from Humphrey Lee from Dowling & Partners. Humphrey, please go ahead.

Good morning. And thank you for taking my questions. My first question is related to the reservice update on recoveries for disability. I understand that as a GAAP exercise for this quarter, but as you go through your fourth-quarter cash flow testing, could you be updating the recovery assumptions for your LTD as well and if that is so, could that have a capital benefits in you cash flow testing?

Yeah. Humphrey, it's Steve, it's probably a little premature to really discuss our year-end cash flow testing and asset adequacy. Also, the claim reserve construct under a statutory basis is a little bit different than GAAP, GAAP is really strictly best estimate. That -- there is some prescriptive things that we need to think about within the statutory reserving, as well as the minimums we need to think about. In addition to what you described, looking overall legal entity, cash flow test results. So, we'll work through that as we get closer to year-end. And if there's an update there, we can talk about it as we talked to you about our fourth quarter results.

Okay. Got it. And then just another follow-up question on LTD. So I understand that there's a little bit of a long COVID -- but as we think about the cases for COVID, and how they trended maybe 9 to 12 months ago do we see more [Indiscernible] spillover from Short-Term Disability to Long-Term Disability in the coming quarters?

Yeah. Humphrey, it's Mike. And similar to the previous question, I would say tough to predict quarter-to-quarter. But you are right. LTD does operate with a bit of a lag. So certainly as that STD remains elevated, we would expect, just using normal flow-through rates on sustained pressure on LTD incidence over the next few quarters. And again, a lot of that's going to be dependent on what's going on in the external environment. I would take it back to the two levers that we have. One is the best benefits team in the business. It's in the marrow of our bones, is what we do, Disability claims management here at Unum. So we've continued to invest there and feel very good about the recoveries that we're able to do and helping our clients keep their teams productive and back at work. And then the second is dialogue around pricing. As I mentioned, we've been feathering that in and we'll continue to do so on a gradual but steady basis. And that'll help from a loss ratio perspective as well.

Thank you.

Thanks, Humphrey.

Thank you, Humphrey. Our final question is from Josh Shanker from Bank of America. Josh, please go ahead.

Yeah, thank you. This is going to be a process question, I guess. What is the difference between a paid claim and incurred claim in long-term care today? When we look at the good results in long-term care mortality, and whatnot that obviously plays into lower paid and you had taken obviously, assumption review in the third quarter and not including any of the current debt. I'm just trying to figure out how sustainable low mortality could be on near-term results found in assumption reviews? And what's the relationship between the incurred paid right now and the paid -- and the incurred claims and the paid claims?

Hey, Josh, it's Steve. I can take that there were about five questions in there, so I'll try to sort through it and try to get it, I think, what you're aiming at, so let me step back a little bit and just give a little history on the LTC block and the experience that we've seen through COVID. Early on, I would say in the pandemic, we saw two things that were pretty cute. One, was very low on submitted and paid claims incidents. I'd say that has pretty much normalized. And so where we sit today, the levels of both submitted and paid claims for LTC are fairly consistent with what we might have historically seen. So. I would say that impact is kind of run its course on the block. When it comes to mortality, again, early on, very acute impact on our climate mortality. I think if you go back to the second quarter of last year, our excess claimant mortality was somewhere around 30%. That graded down over time to about 15% excess claimant mortality. And where we've sat for the last couple of quarters is about 5% elevated claimant mortality that may continue for a little bit. I'd say that also is the flip side of what we're seeing on the Group Life, where a lot of the mortality now is in the younger ages, which doesn't necessarily impact our LTC block. If I then step back and relate that to how we think about the our GAAP reserve assumption review. We do not really view any of that acute information as being something that we would want to layer into our longer-term reserve assumptions and so we completed our assumption review update here in the third quarter. We really did not impact at all and do not anticipate impacting our GAAP reserves for Long-Term Care this year. We feel good about those liability assumptions and so I would separate those 2 things. Now looking forward, we may continue to see some elevated Claimant mortality in the Block. And I would just anticipate us having the normalized both paid and submitted claim incidents volumes. I do think we may continue to see a slightly lower loss ratio, benefit ratio from our expected 85 to 90 over the long term. But I also do expect when we get on the other side of this, we'll be back in that 85% to 90% range.

Okay. And so I guess I probably have the data to track it. But does the incurred loss ex-reserve assumption reviews pretty much track with the paid loss trends? Are they related if I try and put one over the other?

Josh, I'm trying to get to the question of just the distinction between incurred and pay losses. Are you talking about submitted claims versus paid claims or just the timing?

Yeah. I guess [Indiscernible] submitted and paid. But the 2 are correlated and it's really the assumption review that changes the outlook but over a not too distant gap, the paids and the incurreds should track similarly, I would guess. Is that a reasonable statement?

Yeah, I guess how I would address it is I don't think we've seen any difference in the relationship between submitted, paid, incurred claims over this period of time. I'd say they've kind of trended the same and they're both back to what would be more normalized levels currently.

And what point will you interpolate COVID data into your assumption review?

Yes, I would say, to-date, we've pretty much excluded it. I just -- it's hard to draw any kind of long-term expectations based on what we've seen over the last 18 months. I think we need to get back to a more normalized level of experience and then we can reassess that. But I'll tell you today, we really haven't factored that into how we think about longer-term experience.

Fantastic. Thank you.

Thanks, Josh.

Thank you. We currently have no further questions. And this therefore concludes our call. I will now hand over to Ric McKenney if there are further comments. Thank you.

Very thank you, Robin. And I'd like to thank everybody for joining us today. I'd also like to recognize employees that are listening in today. We in the senior team are most appreciative of everything you're doing to help us fulfill our purpose and I just want to recognize you all today. So with that, we'll wrap up by this course. I look forward to talking to you through the fourth quarter. Thanks everyone.

Thank you, everyone. You may now disconnect your lines.